Dysprosium (165Dy) hydroxide macroaggregates for radiation synovectomy--animal studies.
This paper reports the development of a new chemical formulation, Dy-HMA, to utilise the advantages of dysprosium 165 in radiation synovectomy of certain forms of arthritis. Dy-HMA is a sterile suspension of dysprosium hydroxide macroaggregates (approximately 6 mg Dy/ml) in saline with the majority of particles in the 3-5 microns range. The absence of ferric hydroxide and a higher concentration of dysprosium in the formulation offer advantages over dysprosium ferric hydroxide macroaggregates, Dy-165-FHMA. Biodistribution studies in rats and rabbits with Dy-HMA show less leakage than with Dy-FHMA and considerably less leakage than with yttrium silicate colloid. Rabbits treated with intra-articular injections of Dy-HMA equivalent to 10-30 times the typical clinical dose showed no signs of any toxic effects.
McLaren
A
A
Australian Nuclear Science and Technology Organisation, Lucas Heights, NSW.
Hetherington
E
E
Maddalena
D
D
Snowdon
G
G
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000532:radiotherapy; D004419:Dysprosium / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D010316:Particle Size; D011817:Rabbits; D011868:Radioisotopes / Q000627:therapeutic use*; D051381:Rats; D013583:Synovial Membrane / Q000528:radiation effects*; D014018:Tissue Distribution
D011868:Radioisotopes; D004419:Dysprosium